Abstract
Vaccination against coronavirus disease 2019 (COVID-19) has become an important public health solution. Developing a safe and effective vaccine against COVID-19 is a viable long-term solution to control the pandemic. As one of the two inactivated severe acute respiratory syndrome virus 2 (SARS-CoV-2) vaccines developed in China that entered the WHO emergency use list, Sinopharm BBIBP-CorV, an aluminum-hydroxide-adjuvanted, inactivated whole-virus vaccine, has been widely distributed, with more than 400 million doses administered in more than 40 countries. The evidence of the safety, efficacy, and effectiveness of BBIBP-CorV is gathered and reviewed. We further comment on one of the latest papers that disclosed the effectiveness results between BBIBP-CorV, rAd26-rAd5, and ChAdOx1.
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference27 articles.
1. WHO Coronavirus (COVID-19) Dashboard
https://covid19.who.int/
2. WHO Recommendation COVID-19 Vaccine BIBP/Sinopharm
https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-vaccine-bibp
3. COVID-19 Landscape of Novel Coronavirus Candidate Vaccine Development Worldwide
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
4. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
5. Side Effects and Efficacy of COVID-19 Vaccines among the Egyptian Population
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献